Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Go back to Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 199.71 +3.13 (1.59%)
Previous Close $196.58    52 Week High $333.65 
Open $199.48    52 Week Low $223.02 
Day High $200.98    P/E 25.57 
Day Low $194.74    EPS $7.81 
Volume 1,675,269       

(NASDAQ: IONS) Delayed: 75.89 +1.77 (2.39%)
Previous Close $74.12    52 Week High $62.68 
Open $74.85    52 Week Low $19.59 
Day High $76.56    P/E N/A 
Day Low $74.12    EPS $0.00 
Volume 1,956,125